Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Safety Study of Bilateral Subretinal Timrepigene Emparvovec in Choroideremia
2017-002395-75Phase 2Terminated
- Sponsor
- Nightstar Therapeutics
- Start
- Jul 2017
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of timrepigene emparvovec in choroideremia, sponsored by Nightstar Therapeutics. Primary endpoint: Best-Corrected Visual Acuity (BCVA). Started Jul 2017; status: terminated.
02
Drugs
timrepigene emparvovec
03
Conditions
choroideremia
Beyond the preview
Go deeper on 2017-002395-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002395-75.